Health care options today allow medical professionals to offer more individualised treatment for their patients, targeting specific needs and particular conditions. This healthcare paradigm shift is being driven by a combination of factors, including:

• advances in technologies,
• a greater understanding of genetics, and
• improved knowledge about the physiological basis of disease.

Advances in biomedical imaging allow increasingly precise and accurate diagnostic information to be gathered, leading to improvements in treatment of conditions such as cancer, and neurological disorders such as epilepsy and stroke.

In cancers, for example, many tumours seem to look the same. However, there are major differences in the genetic and physiological makeup of different cancers which in turn requires the development of specific treatment options. Biomedical imaging is one method that can identify the differences in tumours, allowing clinicians to better understand a condition and prescribe a personalised patient management plan. At the same time, patients are demanding the application of these new technologies and information produced for planning and managing their treatment.

CRCBID has been formed to accelerate the development of new imaging technologies and systems that can use Positron Emission Tomography (PET) to assist clinicians to predict or diagnose a condition’s existence and scope , to plan treatment and ongoing management, to preview how treatment may proceed, and to conduct ongoing monitoring of how a condition responds to treatment.

CRCBID's research outcomes